Defining a Role for Novel Biomarkers in Acute Coronary SyndromesBONACA, Marc P; MORROW, David A.Clinical chemistry (Baltimore, Md.). 2008, Vol 54, Num 9, pp 1424-1431, issn 0009-9147, 8 p.Article

Subclavian stenosis causing angina after coronary artery bypass graftingTSYVINE, Daniel; HARTZELL, Maryanne; BONACA, Marc P et al.Medical journal of Australia. 2009, Vol 190, Num 6, pp 331-332, issn 0025-729X, 2 p.Article

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromesRØYSLAND, Ragnhild; BONACA, Marc P; OMLAND, Torbjørn et al.Heart (London 1996). 2012, Vol 98, Num 10, pp 786-791, issn 1355-6037, 6 p.Article

Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trialKADAKIA, Mitul B; FOX, Caroline S; SCIRICA, Benjamin M et al.Heart (London 1996). 2011, Vol 97, Num 21, pp 1782-1787, issn 1355-6037, 6 p.Article

[Official Highlights Reports from the European Society of Cardiology (ESC) Congress 2013, Amsterdam, Netherland]GIUGLIANO, Robert P; BONACA, Marc P; UDELL, Jacob A et al.Journal of the American College of Cardiology. 2013, issn 0735-1097, 31 p., NSSerial Issue

Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)BONACA, Marc P; WIVIOTT, Stephen D; SABATINE, Marc S et al.The American journal of cardiology. 2007, Vol 99, Num 3, pp 344-348, issn 0002-9149, 5 p.Article

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialSCIRICA, Benjamin M; BONACA, Marc P; TENDERA, Michal et al.Lancet (British edition). 2012, Vol 380, Num 9850, pp 1317-1324, issn 0140-6736, 8 p.Article

Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic StrokeMORROW, David A; ALBERTS, Mark J; MOHR, Jay P et al.Stroke (1970). 2013, Vol 44, Num 3, pp 691-698, issn 0039-2499, 8 p.Article

Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome Observations From PROVE IT-TIMI 22BONACA, Marc P; MORROW, David A; BRAUNWALD, Eugene et al.Arteriosclerosis, thrombosis, and vascular biology. 2011, Vol 31, Num 1, pp 203-210, issn 1079-5642, 8 p.Article

Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel―Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial InfarctionMORROW, David A; WIVIOTT, Stephen D; ANTMAN, Elliott M et al.Circulation (New York, N.Y.). 2009, Vol 119, Num 21, pp 2758-2764, issn 0009-7322, 7 p.Article

Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50BONACA, Marc P; SCIRICA, Benjamin M; CREAGER, Mark A et al.Circulation (New York, N.Y.). 2013, Vol 127, Num 14, pp 1522-1529, issn 0009-7322, 8 p.Article

American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)BONACA, Marc P; WIVIOTT, Stephen D; BRAUNWALD, Eugene et al.Circulation (New York, N.Y.). 2012, Vol 125, Num 4, pp 577-583, issn 0009-7322, 7 p.Article

Prospective Evaluation of Pregnancy-Associated Plasma Protein-A and Outcomes in Patients With Acute Coronary SyndromesBONACA, Marc P; SCIRICA, Benjamin M; SABATINE, Marc S et al.Journal of the American College of Cardiology. 2012, Vol 60, Num 4, pp 332-338, issn 0735-1097, 7 p.Article

Role of ST2 in Non―ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 TrialKOHLI, Payal; BONACA, Marc P; KAKKAR, Rahul et al.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, pp 257-266, issn 0009-9147, 10 p.Article

Prognostic Performance of Multiple Biomarkers in Patients With Non―ST-Segment Elevation Acute Coronary SyndromeO'MALLEY, Ryan G; BONACA, Marc P; SCIRICA, Benjamin M et al.Journal of the American College of Cardiology. 2014, Vol 63, Num 16, pp 1644-1653, issn 0735-1097, 10 p.Article

Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 TrialBONACA, Marc P; SCIRICA, Benjamin M; BRAUNWALD, Eugene et al.Journal of the American College of Cardiology. 2014, Vol 64, Num 22, pp 2309-2317, issn 0735-1097, 9 p.Article

New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 TrialBONACA, Marc P; SCIRICA, Benjamin M; BRAUNWALD, Eugene et al.Journal of the American College of Cardiology. 2014, Vol 64, Num 22, pp 2318-2326, issn 0735-1097, 9 p.Article

Vorapaxar in the Secondary Prevention of Atherothrombotic EventsMORROW, David A; BRAUNWALD, Eugene; OUDE OPHUIS, A. J et al.The New England journal of medicine. 2012, Vol 366, Num 15, pp 1404-1413, issn 0028-4793, 10 p.Article

Antithrombotics in Acute Coronary SyndromesBONACA, Marc P; GABRIEL STEG, Philippe; FELDMAN, Laurent J et al.Journal of the American College of Cardiology. 2009, Vol 54, Num 11, pp 969-984, issn 0735-1097, 16 p.Article

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic lschemic Events (TRA 2°P)-TIMI 50 trialMORROW, David A; SCIRICA, Benjamin M; FOX, Keith A. A et al.The American heart journal. 2009, Vol 158, Num 3, pp 335-341, issn 0002-8703, 7 p.Article